PEL
MCID: PRM042
MIFTS: 57

Primary Effusion Lymphoma (PEL)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Effusion Lymphoma

MalaCards integrated aliases for Primary Effusion Lymphoma:

Name: Primary Effusion Lymphoma 53 59 73
Pel 53 59
Body Cavity-Based Lymphoma 59
Lymphoma, Aids-Related 73
Aids-Related Lymphoma 53
Lymphoma Aids-Related 55

Characteristics:

Orphanet epidemiological data:

59
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 59 ORPHA48686
MESH via Orphanet 45 D054685
UMLS via Orphanet 74 C1292753
ICD10 via Orphanet 34 C83.8

Summaries for Primary Effusion Lymphoma

MalaCards based summary : Primary Effusion Lymphoma, also known as pel, is related to human herpesvirus 8 and plasmablastic lymphoma. An important gene associated with Primary Effusion Lymphoma is BCL6 (BCL6, Transcription Repressor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Doxorubicin and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are dyspnea and immunodeficiency

Wikipedia : 76 Primary effusion lymphoma (PEL) is a B-cell lymphoma, presenting with a malignant effusion without a... more...

Related Diseases for Primary Effusion Lymphoma

Diseases related to Primary Effusion Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 32.6 BCL6 IL6
2 plasmablastic lymphoma 32.5 BCL6 MYC
3 kaposi sarcoma 32.5 IL6 MYC VEGFA
4 lymphoma 31.3 BCL6 MALT1 MYC TCL1A
5 multicentric castleman disease 30.3 BCL6 IL6
6 castleman disease 30.2 BCL6 IL6 VEGFA
7 acquired immunodeficiency syndrome 29.9 BCL6 IL6 MYC
8 richter's syndrome 29.9 IRF4 MYC
9 autoimmune lymphoproliferative syndrome, type v 29.8 BCL6 TCL1A
10 diffuse large b-cell lymphoma 29.7 BCL6 IRF4 MALT1 MYC
11 follicular lymphoma 29.7 BCL6 IRF4 MYC
12 lung lymphoma 29.6 BCL6 MALT1
13 b-cell lymphomas 29.6 BCL6 CASP3 IRF4 MALT1 MYC TCL1A
14 myeloma, multiple 29.4 CASP3 IL6 IRF4 MYC VEGFA
15 hepatocellular carcinoma 29.3 CASP3 IL6 MYC TNFSF10 VEGFA
16 lymphoma aids related 11.7
17 sarcoma 10.7
18 hepatitis 10.3
19 hepatitis c 10.2
20 critical limb ischemia 10.2 IL6 VEGFA
21 hepatitis c virus 10.2
22 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 BCL6 MYC
23 spinal disease 10.2 IL6 VEGFA
24 blood group, globoside system 10.2 IL6 VEGFA
25 poems syndrome 10.2 IL6 VEGFA
26 macular retinal edema 10.2 IL6 VEGFA
27 liver cirrhosis 10.2
28 central retinal vein occlusion 10.2 IL6 VEGFA
29 gastric lymphoma 10.1 BCL6 VEGFA
30 eales disease 10.1 IL6 VEGFA
31 post-transplant lymphoproliferative disease 10.1 IL6 TNFSF10
32 plasma cell neoplasm 10.1 IL6 MYC
33 colon lymphoma 10.1 BCL6 IRF4
34 retinal artery occlusion 10.1 IL6 VEGFA
35 cowpox 10.1 CASP3 IL6
36 nasopharyngeal disease 10.1 CASP3 MYC VEGFA
37 pharynx cancer 10.1 CASP3 MYC VEGFA
38 cervix disease 10.1 CASP3 MYC VEGFA
39 pancytopenia 10.1
40 male reproductive organ cancer 10.1 CASP3 MYC VEGFA
41 colonic disease 10.1 CASP3 MYC VEGFA
42 central nervous system hematologic cancer 10.1 BCL6 IRF4
43 traumatic brain injury 10.1 CASP3 IL6
44 respiratory system cancer 10.1 CASP3 MYC VEGFA
45 colon adenoma 10.1 CASP3 VEGFA
46 nervous system cancer 10.1 CASP3 MYC VEGFA
47 endocrine gland cancer 10.1 CASP3 MYC VEGFA
48 pancreas adenocarcinoma 10.1 CASP3 MYC VEGFA
49 rosacea 10.1 IL6 VEGFA
50 fallopian tube carcinoma 10.1 MYC VEGFA

Graphical network of the top 20 diseases related to Primary Effusion Lymphoma:



Diseases related to Primary Effusion Lymphoma

Symptoms & Phenotypes for Primary Effusion Lymphoma

Human phenotypes related to Primary Effusion Lymphoma:

59 32 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002094
2 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
3 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
4 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
5 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
6 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
7 pericardial effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0001698
8 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CASP3 MALT1 TNFRSF10B TNFSF10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CASP3 MALT1 MYC TNFRSF10B TNFSF10

MGI Mouse Phenotypes related to Primary Effusion Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 BCL6 CASP3 IL6 IRF4 MALT1 MYC
2 endocrine/exocrine gland MP:0005379 9.91 BCL6 CASP3 IL6 MYC SPI1 TNFSF10
3 homeostasis/metabolism MP:0005376 9.86 BCL6 CASP3 IL6 IRF4 MYC SPI1
4 immune system MP:0005387 9.81 BCL6 CASP3 IL6 IRF4 MALT1 MYC
5 liver/biliary system MP:0005370 9.43 BCL6 IL6 MYC SPI1 TNFSF10 VEGFA
6 neoplasm MP:0002006 9.1 IL6 IRF4 MYC SPI1 TNFSF10 VEGFA

Drugs & Therapeutics for Primary Effusion Lymphoma

Drugs for Primary Effusion Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
3
Zidovudine Approved Phase 2,Not Applicable 30516-87-1 35370
4
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
5
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
6
Etoposide Approved Phase 2,Phase 1,Not Applicable 33419-42-0 36462
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Bevacizumab Approved, Investigational Phase 2 216974-75-3
9
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
10
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
11
leucovorin Approved Phase 2,Not Applicable 58-05-9 6006 143
12
Trimethoprim Approved, Vet_approved Phase 2 738-70-5 5578
13
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
14
Levoleucovorin Approved, Investigational Phase 2,Not Applicable 68538-85-2
15
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
16
Bleomycin Approved, Investigational Phase 2,Not Applicable 11056-06-7 5360373
17
Methotrexate Approved Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
18
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
19
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
20
Fluorouracil Approved Phase 2 51-21-8 3385
21
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
22
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
23
Vincristine Approved, Investigational Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
24
Cytarabine Approved, Investigational Phase 2,Not Applicable 147-94-4 6253
25
Sulfamethoxazole Approved Phase 2 723-46-6 5329
26
Ifosfamide Approved Phase 2 3778-73-2 3690
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Allopurinol Approved Phase 2,Not Applicable 315-30-0 2094
29
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
30
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
31
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
32
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
33
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
34
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
35
Nivolumab Approved Phase 2 946414-94-4
36
Cortisone acetate Approved, Investigational Phase 1, Phase 2 1950-04-4, 50-04-4 5745
37
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 59-30-3 6037
39
Doxil Approved June 1999 Phase 2,Phase 1,Not Applicable 31703
40
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
41
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
42 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
43 Immunosuppressive Agents Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Phytogenic Phase 2,Phase 1,Not Applicable
45 Etoposide phosphate Phase 2,Phase 1,Not Applicable
46 Antibiotics, Antitubercular Phase 2,Phase 1,Not Applicable
47 Reverse Transcriptase Inhibitors Phase 2,Not Applicable
48 Anti-HIV Agents Phase 2,Not Applicable
49 Antineoplastic Agents, Alkylating Phase 2,Phase 1,Not Applicable
50 Immunologic Factors Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
2 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
3 SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
4 Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
5 EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
6 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00003388 Phase 2 cyclophosphamide;cytarabine;methotrexate;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
7 A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL Completed NCT00799136 Phase 2 R-EPOCH and cART
8 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
9 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Completed NCT00003114 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
10 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide
11 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
12 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
13 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Active, not recruiting NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
14 Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma Terminated NCT00126243 Phase 2 rituximab;CHOP
15 Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas Terminated NCT00183976 Phase 2 Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
16 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
17 Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine
18 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
19 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting NCT03220022 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ibrutinib;Prednisone;Vincristine Sulfate
20 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
21 Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma Active, not recruiting NCT00569985 Phase 1 carmustine;cyclophosphamide;etoposide
22 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting NCT01961063 Phase 1 busulfan
23 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting NCT02337985 Phase 1 Prednisone;Etoposide;Doxorubicin Hydrochloride;Vincristine Sulfate;Cyclophosphamide
24 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
25 Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy Completed NCT03690895
26 Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Completed NCT00026728
27 Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members Completed NCT00000703 Not Applicable Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Zidovudine;Dexamethasone
28 124I-FIAU Imaging in EBV and KSHV Associated Cancers Completed NCT00982449 Not Applicable
29 Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma Recruiting NCT02823327
30 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
31 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Active, not recruiting NCT02652715 Not Applicable
32 Prospective Study of Lymphoproliferative Diseases Withdrawn NCT01704742
33 Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Withdrawn NCT01769911 Not Applicable carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine
34 Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer Withdrawn NCT00499668 Not Applicable aprepitant;ondansetron hydrochloride

Search NIH Clinical Center for Primary Effusion Lymphoma

Genetic Tests for Primary Effusion Lymphoma

Anatomical Context for Primary Effusion Lymphoma

MalaCards organs/tissues related to Primary Effusion Lymphoma:

41
B Cells, T Cells, Liver, Brain, Kidney, Colon, Endothelial

Publications for Primary Effusion Lymphoma

Articles related to Primary Effusion Lymphoma:

(show top 50) (show all 527)
# Title Authors Year
1
KSHV/HHV8-Associated Extracavitary Primary Effusion Lymphoma Presenting as Multiple Lymphomatous Polyposis. ( 29505765 )
2018
2
Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation. ( 29207179 )
2018
3
MALT1 protease activity in primary effusion lymphoma. ( 29560084 )
2018
4
The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL). ( 29669178 )
2018
5
Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. ( 29739902 )
2018
6
A case of Epstein-Barr virus-negative human immunodeficiency virus-related primary effusion lymphoma. ( 29454632 )
2018
7
Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. ( 29207182 )
2018
8
Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient. ( 29619259 )
2018
9
33-year-old HIV-positive patient presenting with primary effusion lymphoma. ( 30455942 )
2018
10
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. ( 30328487 )
2018
11
Primary effusion lymphoma of the pleural space: Report of a rare complication of cardiac transplant with review of the literature. ( 30276937 )
2018
12
'Discovering' primary effusion lymphoma in Malawi. ( 30212407 )
2018
13
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. ( 29954751 )
2018
14
Primary effusion lymphoma: current perspectives. ( 29988764 )
2018
15
Daratumumab in Primary Effusion Lymphoma. ( 30110586 )
2018
16
Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. ( 30111820 )
2018
17
Biology and management of primary effusion lymphoma. ( 30154110 )
2018
18
Biofilm Formation by the Acidophile Bacterium Acidithiobacillus thiooxidans Involves c-di-GMP Pathway and Pel exopolysaccharide. ( 29466318 )
2018
19
Genome-wide identification and expression analyses of the pectate lyase (PEL) gene family in cotton (Gossypium hirsutum L.). ( 30200887 )
2018
20
Expression and subcellular localization of the KSHV K15P protein during latency and lytic reactivation in primary effusion lymphoma cells. ( 28835496 )
2017
21
Correction for Cousins et al., "Human Herpesvirus 8 Viral Interleukin-6 Signaling through gp130 Promotes Virus Replication in Primary Effusion Lymphoma and Endothelial Cells". ( 29138334 )
2017
22
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
23
Diversity of human herpesvirus 8 genotypes in patients with AIDS and non-AIDS associated Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in Argentina. ( 28617968 )
2017
24
Post-transplant Lymphoproliferative Disorder Presented in a Form of Primary Effusion Lymphoma with t (8; 14). ( 28667038 )
2017
25
SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells. ( 28393364 )
2017
26
Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. ( 28922425 )
2017
27
Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma presenting with cardiac tamponade: A case report. ( 29068981 )
2017
28
Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. ( 28092744 )
2017
29
Primary effusion lymphoma in Taiwan shows two distinctive clinicopathological subtypes with rare human immunodeficiency virus association. ( 29206290 )
2017
30
1, 25(OH)2 D3 Induces Reactivation and Death of Kaposi's Sarcoma-Associated Herpesvirus of Primary Effusion Lymphoma cells. ( 28963501 )
2017
31
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. ( 29021516 )
2017
32
Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. ( 28146424 )
2017
33
Correction for Cousins and Nicholas, "Role of Human Herpesvirus 8 Interleukin-6-Activated gp130 Signal Transducer in Primary Effusion Lymphoma Cell Growth and Viability". ( 29191994 )
2017
34
Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma. ( 28653223 )
2017
35
Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. ( 28468596 )
2017
36
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. ( 28459467 )
2017
37
An intrasinusoidal extracavitary variant of primary effusion lymphoma. ( 28798059 )
2017
38
InA vitro and inA vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida. ( 29048633 )
2017
39
Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge. ( 28880367 )
2017
40
Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy. ( 28580733 )
2017
41
Rapidly progressive intravascular primary effusion lymphoma in an HIV-positive renal transplant recipient. ( 28815752 )
2017
42
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. ( 28847988 )
2017
43
Primary effusion lymphoma: current concepts and management. ( 28399009 )
2017
44
A unique case of primary effusion lymphoma-like lymphoma showing disappearance and recurrence of the body cavity effusion. ( 29263988 )
2017
45
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. ( 28432410 )
2017
46
Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma. ( 28481873 )
2017
47
Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. ( 29105119 )
2017
48
Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. ( 28084853 )
2017
49
YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. ( 28396094 )
2017
50
Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells. ( 29267216 )
2017

Variations for Primary Effusion Lymphoma

Copy number variations for Primary Effusion Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Primary Effusion Lymphoma

Search GEO for disease gene expression data for Primary Effusion Lymphoma.

Pathways for Primary Effusion Lymphoma

Pathways related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 BCL6 CASP3 IL6 IRF4 MYC VEGFA
2
Show member pathways
12.76 CASP3 IL6 MYC TCL1A VEGFA
3
Show member pathways
12.74 CASP3 IL6 TNFRSF10B TNFSF10 VEGFA
4
Show member pathways
12.7 CASP3 IL6 MALT1 VEGFA
5
Show member pathways
12.69 CASP3 MYC SPI1 VEGFA
6
Show member pathways
12.61 CASP3 IL6 TNFRSF10B TNFSF10
7 12.58 CASP3 IL6 MYC SPI1 VEGFA
8
Show member pathways
12.53 CASP3 IRF4 MYC TNFRSF10B TNFSF10
9
Show member pathways
12.48 CASP3 TNFRSF10B TNFSF10 VEGFA
10
Show member pathways
12.44 CASP3 TNFRSF10B TNFSF10 VEGFA
11 12.23 BCL6 IRF4 MALT1 SPI1 TNFRSF10B
12
Show member pathways
12.22 CASP3 MYC TNFRSF10B
13
Show member pathways
12.15 BCL6 IRF4 MALT1 MYC
14
Show member pathways
12.14 CASP3 TNFRSF10B TNFSF10
15 12.13 CASP3 IL6 MYC
16 12.13 CASP3 MYC VEGFA
17
Show member pathways
12.09 CASP3 TNFRSF10B TNFSF10
18 12.07 CASP3 IL6 MALT1
19 12.02 CASP3 IL6 VEGFA
20 11.98 CASP3 MYC VEGFA
21 11.97 BCL6 IL6 MYC SPI1
22
Show member pathways
11.93 BCL6 IL6 TNFSF10
23 11.92 CASP3 MALT1 MYC TNFRSF10B TNFSF10
24 11.9 IL6 MYC VEGFA
25 11.89 CASP3 IL6 MYC VEGFA
26
Show member pathways
11.88 IL6 MYC TNFRSF10B TNFSF10
27 11.84 CASP3 IL6 MYC
28 11.72 CASP3 IL6 VEGFA
29 11.56 IL6 IRF4 SPI1
30 11.47 BCL6 IRF4 SPI1
31 11.24 IRF4 SPI1
32 11.21 IL6 MYC
33 11.16 CASP3 IL6 MYC VEGFA
34 11.08 BCL6 IL6 IRF4 MYC VEGFA
35
Show member pathways
10.97 MYC TNFSF10
36 10.89 CASP3 IL6 TNFRSF10B TNFSF10
37 10.69 IRF4 SPI1

GO Terms for Primary Effusion Lymphoma

Biological processes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 IL6 IRF4 MYC SPI1 VEGFA
2 positive regulation of transcription, DNA-templated GO:0045893 9.89 IL6 IRF4 MYC SPI1
3 positive regulation of cell proliferation GO:0008284 9.87 IL6 MYC TCL1A VEGFA
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.71 MALT1 TNFRSF10B TNFSF10
5 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.58 TNFRSF10B TNFSF10
6 positive regulation of DNA binding GO:0043388 9.58 IRF4 MYC
7 positive regulation of mesenchymal cell proliferation GO:0002053 9.55 MYC VEGFA
8 positive regulation of apoptotic process GO:0043065 9.55 BCL6 CASP3 IL6 TNFRSF10B TNFSF10
9 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.54 CASP3 TNFRSF10B TNFSF10
10 activation of NF-kappaB-inducing kinase activity GO:0007250 9.52 MALT1 TNFRSF10B
11 myeloid dendritic cell differentiation GO:0043011 9.51 IRF4 SPI1
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.5 IL6 TCL1A VEGFA
13 negative regulation of apoptotic process GO:0043066 9.5 BCL6 CASP3 IL6 MALT1 MYC TCL1A
14 macrophage differentiation GO:0030225 9.49 SPI1 VEGFA
15 positive regulation of glial cell proliferation GO:0060252 9.48 IL6 MYC
16 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.46 TNFRSF10B TNFSF10
17 positive regulation of mitochondrial membrane potential GO:0010918 9.43 MYC TCL1A
18 positive regulation of cellular component movement GO:0051272 9.4 BCL6 VEGFA
19 T-helper 17 cell lineage commitment GO:0072540 9.26 IL6 IRF4
20 cytokine-mediated signaling pathway GO:0019221 9.1 BCL6 CASP3 IL6 IRF4 MYC VEGFA

Molecular functions related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.7 BCL6 CASP3 IL6 IRF4 MALT1 MYC
2 sequence-specific DNA binding GO:0043565 9.62 BCL6 IRF4 MYC SPI1
3 identical protein binding GO:0042802 9.55 BCL6 MALT1 TCL1A TNFSF10 VEGFA
4 cytokine activity GO:0005125 9.43 IL6 TNFSF10 VEGFA
5 TRAIL binding GO:0045569 8.62 TNFRSF10B TNFSF10

Sources for Primary Effusion Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....